<DOC>
	<DOCNO>NCT01037907</DOCNO>
	<brief_summary>To determine efficacy safety oral drug ( BGC20-0134 ) patient relapse remit multiple sclerosis . Specifically , cumulative number new gadolinium enhance lesion 24 week treatment BGC20-0134 .</brief_summary>
	<brief_title>A Study Orally Administered BGC20-0134 ( Structured Lipid ) Patients With Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description>Primary outcome measure : The cumulative number new GdE T1 lesion develop treatment . Secondary outcome measure : - MRI : - Cumulative number total GdE T1 lesion develop treatment - Cumulative number new T2 lesion - Patients free GdE ( T1-weighted ) lesion week 24 - Change volume GdE T1 - Brain atrophy - Cumulative number new T1 hypointense lesion ( black hole ) - Disease burden , T1 T2 lesion activity week 48 . - Number clinical relapse baseline end treatment . â€¢ Change Expanded Disability Status Scale ( EDSS ) - Number patient require methylprednisolone treatment relapse . - Serum level pro- anti-inflammatory cytokine . - Quality life ( MSQOL-54 ) Eligibility Criteria MS-Related inclusion criterion 1 . Diagnosis relapse MS accord revised 2005 McDonald criterion . 2 . Has show disease activity define 1 MS attack within last year document prior medical note presence active lesion historical scan either ( base radiology report investigator review MRI ) : 1 . Gd-enhancing scan obtain last year , 2. new T2 lesion two scan obtain within last year . 3 . A minimum total 9 T2 lesion report recent MRI obtain within 1 month prior screen visit . 3 . Baseline EDSS score 0 - 5.5 . 4 . Has refuse treat approved disease modify therapy available MS , reason investigator fully inform patient relate benefit potential adverse event associate treatment . Also , patient treatment prove intolerable . Exclusion Criteria : 1 . Has experience MS relapse receive systemic corticosteroid adrenocorticotropic hormone ( ACTH ) previous 1 month . 2 . Has secondary progressive ( SPMS ) , progressive relapsing ( PRMS ) , primary progressive MS ( PPMS ) . 3 . Has receive follow agent treat MS ( approve unapproved ) : - Within previous 3 month : interferon beta , glatiramer acetate , intravenous immunoglobulin plasmapheresis . - Within previous 12 month : natalizumab , daclizumab , cytapheresis , azathioprine , cladribine , cyclophosphamide , methotrexate , mitoxantrone , mycophenolate , pixantrone , sirolimus , tacrolimus , agent typically use prevent transplant rejection cancer chemotherapy , exclude hormonal treatment . - Ever receive : stem cell bone marrow transplant , total lymphoid irradiation , vaccine therapy MS , monoclonal antibody whose effect may longer 1 year ( alemtuzumab rituximab ) . - Within previous 3 month : agent give non-symptomatic treatment MS include , include over-the-counter , herbal nutritional supplement . However , agent take primarily treat another medical condition , allow long dose unchanged within previous 3 month unlikely change week</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Diagnosis relapse MS accord revised 2005 McDonald criterion Has show disease activity define 1 MS attack within last year document prior medical note presence active lesion historical scan either ( base radiology report investigator review MRI ) : Gdenhancing scan obtain last year , new T2 lesion two scan obtain within last year A minimum total 9 T2 lesion report recent MRI obtain within 1 month prior screen visit Baseline EDSS score 0 5.5 Has refuse treat approved disease modify therapy available MS , reason investigator fully inform patient relate benefit potential adverse event associate treatment . Also , patient treatment prove intolerable Has experience MS relapse receive systemic corticosteroid adrenocorticotropic hormone ( ACTH ) previous 1 month Has secondary progressive ( SPMS ) , progressive relapsing ( PRMS ) , primary progressive MS ( PPMS ) . Has receive follow agent treat MS ( approve unapproved ) : Within previous 3 month : interferon beta , glatiramer acetate , intravenous immunoglobulin plasmapheresis Within previous 12 month : natalizumab , daclizumab , cytapheresis , azathioprine , cladribine , cyclophosphamide , methotrexate , mitoxantrone , mycophenolate , pixantrone , sirolimus , tacrolimus , agent typically use prevent transplant rejection cancer chemotherapy , exclude hormonal treatment Ever receive : stem cell bone marrow transplant , total lymphoid irradiation , vaccine therapy MS , monoclonal antibody whose effect may longer 1 year ( alemtuzumab rituximab ) Within previous 3 month : agent give nonsymptomatic treatment MS include , include overthecounter , herbal nutritional supplement . However , agent take primarily treat another medical condition , allow long dose unchanged within previous 3 month unlikely change week 24 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Oral treatment MS</keyword>
	<keyword>Oral drug multiple sclerosis</keyword>
	<keyword>Oral RRMS</keyword>
	<keyword>Oral relapse remit multiple sclerosis</keyword>
	<keyword>Gamma Linolenic Acid</keyword>
	<keyword>GLA</keyword>
	<keyword>Fatty acid</keyword>
	<keyword>Triglyceride</keyword>
	<keyword>Structured lipid</keyword>
	<keyword>MRI</keyword>
	<keyword>Magnetic resonance imaging</keyword>
	<keyword>gadolinium enhance lesion</keyword>
	<keyword>expand disability status scale</keyword>
	<keyword>EDSS</keyword>
	<keyword>Demyelination</keyword>
	<keyword>Remyelination</keyword>
	<keyword>TGFB1</keyword>
	<keyword>Transforming growth factor beta 1</keyword>
	<keyword>cytokine</keyword>
	<keyword>disease modify therapy</keyword>
	<keyword>immunomodulator</keyword>
	<keyword>Anti inflammatory</keyword>
	<keyword>Pro inflammatory</keyword>
	<keyword>TNF alpha</keyword>
	<keyword>interleukin 1 beta</keyword>
	<keyword>interferon gamma</keyword>
	<keyword>Fayaz Master</keyword>
	<keyword>Omega 6</keyword>
	<keyword>Polyunsaturated fatty acid</keyword>
	<keyword>Cytokine balance</keyword>
	<keyword>Pleneva TM</keyword>
	<keyword>BGC20-0134</keyword>
	<keyword>RRMS</keyword>
</DOC>